Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concentration [IC 50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells. BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concentrations ranging from 1.5 to 2.4 nM and selectivity indices up to 8,700 relative to cytotoxicity. BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals. BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants. BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with high-level INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG. In dose-escalation experiments conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, respectively. A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus. All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals. A high barrier to in vitro resistance emergence for both BIC and DTG was also observed in viral breakthrough studies in the presence of constant clinically relevant drug concentrations. The overall virologic profile of BIC supports its ongoing clinical investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the last 14 years, four more INSTIs were approved for treatment of HIV infection: elvitegravir, dolutegravir, bictegravir and cabotegravir147–150.”
From Structure and function of retroviral integrase (2022) · cites this paper as [149]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J.-G., Domingo, P., Brennan, C., Almond, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70257-3 · Cited by 379
Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Research works printed but not linked: 7
- Lepik KJ, Yip B, Robbins M, Woods C, Lima VD, McGovern RA, Zhang WW, Barrios R, Montaner JSG, Harrigan PR. 2016. Prevalence and incidence of integrase drug resistance in BC, Canada 2009-2015. Abstr 23rd Conf Retroviruses Opportunistic Infect, abstr 492LB.
- ViiV Healthcare. 2015. Tivicay 50 mg film-coated tablets. ViiV Healthcare, Middlesex, United Kingdom.
- Lazerwith SE, Cai R, Chen X, Desai MC, Eng S, Jacques R, Ji M, Martin H, McMahon C, Mish M, Morganelli P, Mwangi J, Pyun HJ, Schmitz U, Stepan G, Szwarcberg J, Tang J, Tsiang M, Wang J, White K, Wiser L, Zack J, Jin H. 2016. Discovery of bictegravir (GS-9883), a novel, unboosted, once-daily HIV-1 integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and in vitro resistance profile. ASM Microbe 2016, poster 414.
- Pozniak A, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Hagins D, Buendia CB, Dorey D, Griffith S, Min S. Dolutegravir (DTG) versus raltegravir (RAL) in ART-experienced, integrase-naive subjects: 24 week interim results from SAILING (ING111762). Abstr 20th Conf Retroviruses Opportunistic Infect, abstr 179LB.
- Jones G, Ledford RM, Yu F, Chen X, Miller MD, Tsiang M, McColl DJ. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Abstr 14th Conf Retroviruses Opportunistic Infect, abstr 627.
- Abram M, Margot N, Barnes T, Ram R, Chen X, White K, Miller M, Callebaut C. 2014. Clinical impact and characterization of HIV integrase inhibitor resistance associated with T97A: a low-level polymorphic integrase mutation, abstr POH-017. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
- 10.1310/hct1504-218 · DOI
Cited by
Items 301–331 of 331
Brado, D. (2020) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-21656
Structural And Biochemical Studies Of Hiv-1 Integration And Inhibition
Eilers, G. (2001) · Scholarly Commons (University of Pennsylvania)
HIV-1 Integrase C-terminal Domain Mutations Regulate ALLINI SensitivityPreprint
Kumar, A., Dinh, T., Mugisha, C. S., Boateng, A. T., Zhou, Q., Kvaratskhelia, M., & Kutluay, S. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.22.761050
Amador, C., Ambrosioni, J., Martín‐Carbonero, L., Hidalgo-Tenorio, C., Tiraboschi, J. M., & Moreno, S. (2025) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2026.503056
Prous, C. A., Ambrosioni, J., Carbonero, L. M., Hidalgo-Tenorio, C., Tiraboschi, J. M., & Moreno, S. (2025) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Shafer, R. W., Tao, K., Loosli, T., Abecasis, A. B., Armenia, D., Bwire, G. M., Diaz, R. S., Fokam, J., Girón-Callejas, A. C., Inzaule, S. C., et al. (2026) · Viruses · doi:10.3390/v18060588
Iron-catechol based nanoscale coordination polymers as efficient carriers in HIV/AIDS therapy
Solórzano, R., & de Química, U. A. D. B. D. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I
Rolle, C.-P., D’Antoni, M. L., Corales, R. B., Marongiu, A., Gruber, J., Schreibman, T., Bell, D., Hsiao, C.-B., & Brar, I. (2025) · AIDS Research and Therapy · doi:10.1186/s12981-025-00795-9
Begum, A., Ayesha Begum, K., & P.Sandhya (2020) · International Journal of Pharmacy and Industrial Research
İnsan immünyetmezlik virus-1 (HIV-1) pozitif bireylerde integraz gen mutasyonlarının araştırılması
Özgüler, K. (2019) · Marmara University Open Access System
Drug Discovery Targeting Viral Metalloenzymes
Li, B., Xu, H., Zhou, J., Tang, K., Liu, X., Yang, J., & Zhan, P. (2026) · Wiley eBooks · doi:10.1002/9783527848683.ch10
An Ultra Long-acting Bictegravir Prodrug Nanocrystal with a Shape-shifting Pharmacokinetic Tail
Nayan, M. U. (2024) · DigitalCommons@UNMC
Chen, Y.-C. (2023) · D-Scholarship@Pitt (University of Pittsburgh)
Development of a high-throughput HIV-1 integrase drug screening platform
Bourquin, R. A. (2023) · ResearchOnline at James Cook University (James Cook University) · doi:10.25903/qrbs-0s56
Jadav, T., Rajput, N., Kumar, H., Behera, S. K., & Sengupta, P. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2352462
HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
Murrell, D. E. (2018) · Digital Commons - East Tennessee State University (East Tennessee State University)
Bictegravir/emtricitabine/tenofovir Alafenamide for the Treatment of People Living with HIV
Mallolas, J. (2022) · touchREVIEWS in Infectious Diseases · doi:10.17925/id.2022.1.1.12
GÜNEŞ, F. (2022) · DergiPark
Optimización del manejo clínico de enfermedades infecciosas víricas en usuarios de drogas
Corona‐Mata, D. (2024) · Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)
Antonova, A. A., Vinokurov, A., Kustova, D. D., Pochtovyi, A. A., Ogarkova, D. A., Kuznetsova, A. I., Adgamov, R. R., Tsyganova, E. V., Борисовна, К. И., Plutnitskii, A., et al. (2026) · Viruses · doi:10.3390/v18010147
Agnes, K. (2026) · IAA Journal of Applied Sciences · doi:10.59298/iaajas/2026/1415564
Dubson, I., Gaur, A., Jose, J., Andrews, C., Gaballa, A., & McFarlane, S. I. (2026) · Cureus · doi:10.7759/cureus.106218
Penrose, K. J., Hikichi, Y., Sethi, R., Goetz, B. J., Siffert, L. O., Valiyaparmbil, S. A., Wallis, C. L., McCarthy, C., Wooley, E., Chandran, U. R., et al. (2026) · medRxiv · doi:10.64898/2026.07.02.26356352
Bictegravir/Tenofovir Alafenamide/Emtricitabine in Real-Life: A Multi-Year Experience
Gidari, A., Baranello, E., Pallotto, C., Morosi, S., Papalini, C., Gamboni, G., Malincarne, L., Rosignoli, D., Benvenuto, M. C., Gonnelli, G., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145553
Yin, M., Li, F., Zhang, Q., & 袁子清 (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-14251-0
Jeevanandam, J., Banerjee, S., & Paul, R. (2026) · doi:10.37871/bmpj1113
An efficient approach for the synthesis of dolutegravir and its analogue exploiting flow chemistry
Nqeketo, S. (2023) · Nelson Mandela University Research Repository
Raj, A., Omer, H. B. M., Roy, M. D., Siddika, A., & Sharmin, S. (2026) · BioMed Research International · doi:10.1155/bmri/1672620
Niyigena, E., Greef, J. D., Panin, N., Yombi, J. C., Dreesen, E., Belkhir, L., Haufroid, V., & Elens, L. (2026) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001542
Metadata
- Authors
- Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., Niedziela-Majka, A., Yant, S. R., Yu, H., Kukolj, G., Cihlar, T., Lazerwith, S. E., White, K. L., & Jin, H.
- Affiliations
- Gilead Sciences (United States) (US)
- Gilead Sciences, Foster City, California, USA
- Corresponding author
- White, Kirsten L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-12
- Volume
- 60
- Issue
- 12
- Pages
- 7086-7097
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5118987
- OpenAlex
- W2523305619
- Cited by
- 290
- References
- 50
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 24 · 2023: 25 · 2022: 24 · 2021: 40 · 2020: 37 · 2019: 38 · 2018: 36 · 2017: 18 · 2016: 2
- FWCI
- 28.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- bictegravir, antiviral activity, drug resistance, integrase inhibitors, dolutegravir, raltegravir, elvitegravir, cross-resistance, viral breakthrough, tenofovir alafenamide, emtricitabine, darunavir, drug selectivity
- MeSH terms
- Raltegravir Potassium, Dolutegravir, Amides, Cell Line, Drug Synergism, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Mutation, Oxazines, Piperazines, Pyridones, HIV-1, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.